Key result
An abnormal heart rate recovery of <16 beats/min at 1 minute after a 6-minute walk test was associated with a significantly increased risk of clinical worsening (HR 6.4) in patients with connective tissue disease-associated pulmonary hypertension.
Why the study?
Does abnormal heart rate recovery after the 6-minute walk test predict clinical worsening, hospitalization, and survival in patients with connective tissue disease-associated pulmonary hypertension?
Cohort (n=66)
No
Does abnormal heart rate recovery after the 6-minute walk test predict clinical worsening, hospitalization, and survival in patients with connective tissue disease-associated pulmonary hypertension?
Hazard Ratio: 6.4 (95% CI 2.6–19.2)
Absolute Event Rate: 58% vs 25%
p-value: p=<0.0001
Abnormal heart rate recovery at 1 minute after the 6-minute walk test is a strong predictor of clinical worsening, hospitalization, and mortality in patients with connective tissue disease-associated pulmonary hypertension.
HRR after 6MWT may aid prognostication in CTD-PH; leaves open prospective validation before clinical adoption.
Reduced heart rate recovery (HRR) after exercise is associated with increased mortality in cardiac and pulmonary diseases. We sought to evaluate the association between HRR after the 6-minute walk test (6MWT) and outcomes in patients with connective tissue disease-associated pulmonary hypertension (CTD-PH). Data were obtained by review of the medical records. HRR was defined as the difference in heart rate at the end of the 6MWT and after 1 minute (HRR1), 2 minutes (HRR2), and 3 minutes (HRR3) of rest. All patients with pulmonary hypertension and a diagnosis of systemic sclerosis, systemic lupus erythematosus, or mixed connective tissue disease who underwent the 6MWT between August 1, 2009, and October 30, 2011, were included (n = 66). By Kaplan-Meier analysis, HRR1, HRR2, and HRR3 at different cutoff points were all good predictors, with HRR1 of <16 being the best predictor of time to clinical worsening (log-rank P < 0.0001), hospitalization (log-rank P = 0.0001), and survival (log-rank P < 0.003). By proportional hazards regression, patients with HRR1 of <16 were at increased risk of clinical worsening (hazard ratio [HR]: 6.4 [95% confidence interval (CI): 2.6-19.2]; P < 0.0001], hospitalization (HR: 6.6 [95% CI: 2.4-23]; P < 0.0001), and death (HR: 4.5 [95% CI: 1.6-15.7]; P = 0.003). Patients in the highest tercile (HRR1 of ≥19) were unlikely to have a clinical worsening event (HR: 0.1 [95% CI: 0.04-0.5]; P = 0.001], to be hospitalized (HR: 0.1 [95% CI: 0.02-0.5]; P = 0.001), or to die (HR: 0.3 [95% CI: 0.07-0.9]; P = 0.04]. In conclusion, in patients with CTD-PH, abnormal HRR1 (defined as HRR1 of <16) after the 6MWT is a strong predictor of clinical worsening, time to clinical worsening, survival, and hospitalization.
No takes yet. Share an insight, caveat, or question.
Minai et al. (2015) conducted a cohort in Connective tissue disease-associated pulmonary hypertension (n=66). Heart rate recovery at 1 minute (HRR1) < 16 beats/min vs. HRR1 ≥ 16 beats/min was evaluated on Time to clinical worsening (HR 6.4, 95% CI 2.6-19.2, p=<0.0001). An abnormal heart rate recovery of <16 beats/min at 1 minute after a 6-minute walk test was associated with a significantly increased risk of clinical worsening (HR 6.4) in patients with connective tissue disease-associated pulmonary hypertension.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: